SK, Lilly, respectively, in charge of osteroarthritis pain and mental disorder areas
- "Product promotion to be carried out in each company`s main field"
SK Chemicals has signed a joint sales agreement with Lilly Korea for "Cymbalta (ingredient name: Duloxetine hydrochloride; Duloxetine HCL)," a treatment for depression and osteoarthritis pain which does not adequately respond to nonsteroidal anti-inflammatory drugs (NSAIDs), the company announced on Dec. 15.
Under this agreement, SK Chemicals will be in charge of marketing and sales activities for Cymbalta with regard to its applicability to pain management, particularly osteoarthritis pain, beginning on Jan. 1, 2017. For these activities, the company will use its sales capabilities in the area of arthritis treatment, which have been accumulated through the marketing of Joins and other osteoarthritis drugs. Lilly Korea will be dedicated to marketing and sales activities related to Cymbalta`s applicability to major depression and generalized anxiety disorders.
Since its approval in 2007 as a major depressive disorder drug from the Korean Food and Drug Administration, Cymbalta has been approved consecutively for use in the treatment of diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and osteoarthritis pain that does not adequately respond to non-steroidal anti-inflammatory drugs (NSAIDs). In July 2016, the insurance payment standard for Cymbalta was expanded as an analgesic supplement for cancer neuropathic pain.
"We are delighted to have a new partnership with SK Chemicals, which has built a solid position in the market for pain medicines by providing a wide range of new drug research and development and specialty medicines," said Lily Korea President Paul Henry Huibers. "We hope to complement each other to improve the treatment outcomes of antidepressants as well as a medication for the management of osteoarthritis and diabetic peripheral neuropathic pain, thereby enhancing the patients` quality of life."
"SK Chemicals has established its position as a leading company in the market by launching a variety of products in the field of osteoarthritis," said Han Byeong-ro, CEO of SK Chemicals. "We will focus on expanding the market so that more patients can benefit from innovative, internationally available drugs."
- "Product promotion to be carried out in each company`s main field"
SK Chemicals has signed a joint sales agreement with Lilly Korea for "Cymbalta (ingredient name: Duloxetine hydrochloride; Duloxetine HCL)," a treatment for depression and osteoarthritis pain which does not adequately respond to nonsteroidal anti-inflammatory drugs (NSAIDs), the company announced on Dec. 15.
Under this agreement, SK Chemicals will be in charge of marketing and sales activities for Cymbalta with regard to its applicability to pain management, particularly osteoarthritis pain, beginning on Jan. 1, 2017. For these activities, the company will use its sales capabilities in the area of arthritis treatment, which have been accumulated through the marketing of Joins and other osteoarthritis drugs. Lilly Korea will be dedicated to marketing and sales activities related to Cymbalta`s applicability to major depression and generalized anxiety disorders.
Since its approval in 2007 as a major depressive disorder drug from the Korean Food and Drug Administration, Cymbalta has been approved consecutively for use in the treatment of diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and osteoarthritis pain that does not adequately respond to non-steroidal anti-inflammatory drugs (NSAIDs). In July 2016, the insurance payment standard for Cymbalta was expanded as an analgesic supplement for cancer neuropathic pain.
"We are delighted to have a new partnership with SK Chemicals, which has built a solid position in the market for pain medicines by providing a wide range of new drug research and development and specialty medicines," said Lily Korea President Paul Henry Huibers. "We hope to complement each other to improve the treatment outcomes of antidepressants as well as a medication for the management of osteoarthritis and diabetic peripheral neuropathic pain, thereby enhancing the patients` quality of life."
"SK Chemicals has established its position as a leading company in the market by launching a variety of products in the field of osteoarthritis," said Han Byeong-ro, CEO of SK Chemicals. "We will focus on expanding the market so that more patients can benefit from innovative, internationally available drugs."
SK Chemicals Co. Ltd. published this content on 15 December 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 January 2017 17:00:07 UTC.
Original documenthttp://www.skchemicals.com/en/prcenter/new_view.asp
Public permalinkhttp://www.publicnow.com/view/DAD96F904164F0F63C03BAB7EA2B8BCCE7ECECF6
